Outcomes Capture & Utilization
In numerous clinical publications, Perthera has published results that demonstrate that patients with actionable mutations who were treated with a highly ranked treatment option listed in their Perthera Analysis had significantly higher Progression-Free Survival (PFS) and Overall Survival (OS) rates. These results have been featured at oncology conferences such as ASCO Annual, and in journals such as The Lancet Oncology, AACR, etc.
To view other publications Perthera has contributed to, including our latest breakthrough study published in The Lancet Oncology which demonstrated significantly increased overall survival benefit for pancreatic cancer patients, visit our Publications page
Retrospective Case Series Analysis of RAF Family Alterations in Pancreatic Cancer: Real-World Outcomes From Targeted and Standard Therapies
PERTHERA AT THE ASCO VIRTUAL CONFERENCE 2020
This year’s poster, which focuses on KRAS mutations in patients with Pancreatic Cancer, was published in partnership with physicians from several top-class institutions such as Cedars Sinai, Johns Hopkins and the Cleveland Clinic. The Perthera Precision Oncology Platform was utilized in the study to provide structured, curated clinical outcomes data and ranked, therapeutic recommendations to empower clinical researchers and physicians to make significant strides in the improvement of cancer care.
Click here to be linked to the official ASCO Virtual Annual Conference 2020 poster presentation page, or click on the poster below to download a copy of our poster!
The video below, which features Dr. Andrew Hendifar’s (Cedars Sinai) presentation regarding the clinical study, summarizes some of the key findings.